Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II Trial

2010202 citationsJournal Article

Authors

Stephan Petersenn · University of Duisburg-Essen

Jochen Schopohl · Ludwig-Maximilians-Universität München

Ariel Barkan · University of Duisburg-Essen

Pharis Mohideen · Novartis (Switzerland)

Annamaria Colao · University of Naples Federico II

Roger Abs · University of Antwerp

A. Buchelt

Abstract

Pasireotide is a promising treatment for acromegaly. Larger studies of longer duration evaluating the efficacy and safety of pasireotide in patients with acromegaly are ongoing.

Topics & Keywords

Pituitary Gland Disorders and Treatments Growth Hormone and Insulin-like Growth Factors Neurofibromatosis and Schwannoma Cases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Clinical Endocrinology & Metabolism

Volume 95, Issue 6, pp. 2781-2789

DOI: 10.1210/jc.2009-2272

Field-Weighted Citation Impact: 16.82